COMPLETED

Aging and Reward System Response to Inflammation and Anxiety Study

Talk to us

Conditions

AnhedoniaInflammationAnxietyAgingDepression

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to use an experimental inflammatory challenge to examine whether older adults with symptoms of anxiety experience loss of pleasure or loss of motivation when they are exposed to inflammation. Loss of pleasure or loss of motivation will be evaluated using self-report questionnaires, computer tasks, and during a brain scan.

Official Title

Experimental Model of Depression in Aging: Anxiety, Inflammation, and Reward Mechanisms

Quick Facts

Study Start:2023-03-29
Study Completion:2025-12-08
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT05363527

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:60 Years to 80 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Participants will be required to be in good general health (as evaluated during the phone and in-person baseline session)
  2. * Participants will be aged 60 to 80 years.
  3. * 3/4 the participants (n=30) will be those with clinically significant anxiety as defined by a score of 5 or greater on the GAD-7;
  4. * 1/4 the participants (n=10) will be those with low anxiety as defined by a GAD-7 score of \<5.
  1. * Presence of chronic mental or physical illness (except for anxiety)
  2. * History of allergies, autoimmune, liver, or other severe chronic diseases
  3. * Current and regular use of prescription medications such as steroids, non-steroid anti-inflammatory drugs, aspirin, immune modifying drugs, opioid analgesics, statins, antihypertensive drugs, anti-arrhythmic drugs, and antidepressant medications (none in the last 6 months)
  4. * Nightshift work or time zone shifts (\> 3hrs) within the previous 6 weeks
  5. * Previous history of fainting during blood draws.
  6. * Claustrophobia
  7. * Metal in the body
  8. * Presence of co-morbid medical conditions not limited to but including cardiovascular (e.g., history of acute coronary event, stroke) and neurological diseases (e.g., Parkinson's disease), as well as pain disorders;
  9. * Presence of comorbid inflammatory disorders such as rheumatoid arthritis or other autoimmune disorders;
  10. * Presence of an uncontrolled medical condition that is deemed by the investigators to interfere with the proposed study procedures, or to put the study participant at undue risk;
  11. * Presence of chronic infection, which may elevate pro-inflammatory cytokines;
  12. * Presence of an acute infectious illness in the two weeks prior to an experimental session.
  13. * Current Axis I psychiatric disorders other than anxiety as determined by the Research Version of the Structured Clinical Interview
  14. * Lifetime history of suicide attempt or inpatient psychiatric admission.
  15. * Sleep Disorders: Current history of sleep apnea or nocturnal myoclonus;
  16. * Phase-shift disorder
  17. * Current and/or past regular use of hormone-containing medications including steroids;
  18. * Current and/or past regular use of non-steroid anti-inflammatory drugs;
  19. * Current and/or past regular use of immune modifying drugs that target specific immune responses such as cytokine antagonists;
  20. * Current and/or past regular use of analgesics such as opioids;
  21. * Current and/or past regular use of cardiovascular medications, including antihypertensive, anti-arrhythmic, antianginal, and anticoagulant drugs;
  22. * Current smoking
  23. * Current excessive caffeine use (\>600 mg/day) because of the known effects on pro-inflammatory cytokine levels;
  24. * Evidence of recreational drug use from urine test.
  25. * Body mass index \> 35 because of the effects of obesity on proinflammatory cytokine activity
  26. * Any clinically significant abnormality on screening laboratory tests
  27. * Clinically significant abnormalities in electrocardiogram

Contacts and Locations

Principal Investigator

Chloe C Boyle, PHD
PRINCIPAL_INVESTIGATOR
University of California, Los Angeles

Study Locations (Sites)

Norman Cousins Center for Psychoneuroimmunology, University of California, Los Angeles
Los Angeles, California, 90095
United States

Collaborators and Investigators

Sponsor: University of California, Los Angeles

  • Chloe C Boyle, PHD, PRINCIPAL_INVESTIGATOR, University of California, Los Angeles

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-03-29
Study Completion Date2025-12-08

Study Record Updates

Study Start Date2023-03-29
Study Completion Date2025-12-08

Terms related to this study

Keywords Provided by Researchers

  • anxiety
  • aging
  • anhedonia
  • inflammation

Additional Relevant MeSH Terms

  • Anhedonia
  • Inflammation
  • Anxiety
  • Aging
  • Depression